Biomarin
BioMarin develops and commercialises innovative biopharmaceuticals for rare diseases driven by genetic causes.
Financial Data
-
31st Dec 17 Source: CRO
- €491.6 million turnover
-
€1 million
profit - 300 employees
-
31st Dec 16 Source: CRO
- €377.3 million turnover
-
€0.1 million
profit - 236 employees
- 2 more years available »
Ranking
By Turnover
(€491.6 million)- 157th in Top Companies
- 23rd in Health
By Employees
(300)- 473rd in Top Companies
- 70th in Health
- 300
- €491.6 million
Employees
- Michael O’Donnell CEO/Managing Director
Latest News
- 5:33pm Approval given for €31m floating wind project off the Mayo coast
- 3:55pm Fitzgerald buys Bruxelles as homeowners say bye to negative equity
- 3:55pm What the papers say: Fitzgerald buys Bruxelles and an end to negative equity
- Mar 23 Ecocem prepares to pay dividends of up to €5m
- Mar 23 Eir sued by Dutch provider of ‘DIY’ customer care service